AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 286 min read$ALKS

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

Original reporting
SEC EDGAR 8-K
Published Jul 28, 2026, 11:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$ALKS
Bullish
medium confidence
Mentioned
$ALKS
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALKSBullishMed
01

Why it matters

Traders can reprice ALKS based on the combination of (1) Q2 commercial performance across key proprietary products, (2) updated 2026 profitability expectations (notably EBITDA range), and (3) a scheduled CEO transition that may affect execution confidence.

02

Market read

Fresh Q2 financials and updated 2026 guidance provide actionable inputs for positioning around profitability and execution into upcoming clinical readouts.

03

What to watch

The filing highlights upcoming clinical catalysts (ALKS 7290 ADHD data and LUMRYZ phase 2 idiopathic hypersomnia topline) but does not provide outcomes yet, so near-term upside may be capped until those datasets land.

Relevance 8/10Novelty 7/10Timing: today’s SEC 8-K, pre-market/early session context for Q2 print and 2026 guidance

Background

This is Alkermes’ SEC Form 8-K (Item 2.02) with Q2 2026 financial results and updated full-year 2026 expectations, plus leadership transition details.

Company-level read

Ticker impact

$ALKSBullishMedium confidence
Context

Alkermes reported Q2 2026 results and updated 2026 guidance, including cash/investments rising to $691.6M and CEO transition on Aug 1, 2026.

Expected impact

Likely modest positive bias for the next session as guidance is reaffirmed on key sales lines while profitability expectations improve.

Evidence & confidence

The filing provides fresh, time-sensitive datapoints: Q2 revenue $496.0M vs $390.7M prior year, adjusted EBITDA $139.2M vs $126.5M, cash up to $691.6M, and updated 2026 EBITDA range ($75-$95) while revenue and product net sales ranges remain unchanged.

Market effects

Sector

Reinforces demand and cash-generation trajectory in branded neuroscience/sleep and opioid-use disorder franchises, supporting sentiment toward specialty pharma with commercial portfolios.

Regional

Limited direct regional spillover; primarily affects US-listed specialty pharma sentiment.

Global

Low global macro linkage; more relevant to neuroscience/sleep therapeutics investors.

Counterpoint

What could challenge this read

Despite stronger Q2 revenue, GAAP net loss remains in the updated 2026 range and profitability is still partly driven by non-cash items and transaction adjustments.

Key entities

  • issuer
    Alkermes plc

    Reported Q2 2026 results, updated 2026 guidance, and announced CEO transition effective Aug 1, 2026.

  • executive
    Blair Jackson

    COO stepping into CEO role on Aug 1, 2026.

  • executive
    Richard Pops

    Chairman and CEO transitioning to continue as Chairman after Aug 1, 2026.

Read at source← All news

Related articles

JUL 30
$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

yahoo.com6 min
JUL 25
$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

sleepreviewmag.com5 min
JUL 23
$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.

medscape.com4 min
JUL 21
$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

biopharmadive.com7 min